Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase I study investigates DNA vaccine pTVG-AR for metastatic prostate cancer

Aug. 11, 2015

Inovio and MedImmune establish cancer vaccine collaboration

Aug. 11, 2015

MabVax and Rockefeller University enter into research collaboration agreement

Aug. 11, 2015

The FDA grants orphan drug designation to daratumumab for follicular lymphoma

Aug. 10, 2015

FDA approves IND application for Valor's IGN-002

Aug. 7, 2015

Advaxis receives prostate cancer charity grants to develop ADXS-PSA

Aug. 7, 2015

MedImmune and Mirati to conduct trial combining durvalumab and mocetinostat

Aug. 5, 2015

Anti-GD2 antibody enters phase II trial in osteosarcoma

Aug. 3, 2015

Perjeta regimen approved in E.U. for use before surgery in early-stage breast cancer

Aug. 3, 2015

arGEN-X and University of Bern to develop ARGX-110-based combination therapies

Aug. 3, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...